RBC keeps EUR 10 target for Evotec stock. Price trades 1.56 percent below Xetra close

Published on 10/19/2026 at 09:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month revenue reached EUR 465.00 million on October 13, 2026. Evotec stock costs EUR 2.53 on October 19, 2026, 1.56 percent below Xetra close.

Revenue and guidance shape the view

Preliminary nine-month revenue reached EUR 465.00 million on October 13, 2026.
Evotec kept its 2026 revenue guidance at EUR 570.00 million to EUR 610.00 million.
Evotec stock trades at EUR 2.53 at 9:00 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.56 percent below the Xetra close of October 16, 2026.
RBC Capital Markets kept its Outperform rating and EUR 10.00 target on October 14, 2026.

Geometrisches Bauhaus-Poster in Rot Gelb Blau mit großem Schriftzug PHARMA — Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA steht sinnbildlich für Evotec SE, ISIN DE0005664809, Biotech-Branche, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) trades at EUR 2.53 at Lang & Schwarz on October 19, 2026 at 9:00 a.m. CEST, down 1.56 percent versus the Xetra close of October 16, 2026. The latest analyst signal came from RBC Capital Markets, which kept its Outperform rating and EUR 10.00 price target on October 14, 2026, according to finanzen.ch.

Preliminary figures beat expectations

Evotec announced preliminary revenue of EUR 465.00 million for the first nine months of 2026, alongside an adjusted EBITDA loss of EUR 42.80 million. The figures exceeded current market expectations, but the company said the difference was driven largely by the timing of consensus estimates, according to EQS News on October 13, 2026.

That distinction matters for the full-year picture. Evotec reaffirmed 2026 revenue guidance of EUR 570.00 million to EUR 610.00 million and adjusted EBITDA guidance of minus EUR 70.00 million to minus EUR 105.00 million. The preliminary revenue figure therefore covers 76.23 percent to 81.58 percent of the guided annual range, while the adjusted EBITDA outlook remains negative.

What changed across three dates?

On October 13, 2026, Evotec reported preliminary nine-month revenue of EUR 465.00 million. On October 14, 2026, RBC Capital Markets kept its EUR 10.00 target and Outperform rating. On October 15, 2026, Evotec appointed Joanna Holbrook as chief scientific officer and a board member, effective November 1, 2026, according to Boerse Express.

Which dates matter next?

Evotec is scheduled to publish its full third-quarter and nine-month 2026 results on November 5, 2026, according to EQS News. Joanna Holbrook is due to take up her new role on November 1, 2026, according to Boerse Express.

Stock remains below the target

RBC's EUR 10.00 target stands 295.26 percent above the Lang & Schwarz price of EUR 2.53, using the same euro basis. The contrast is substantial, but the company's unchanged guidance and projected adjusted EBITDA loss leave the November report as the next test of the preliminary improvement.

Evotec was trading at EUR 2.53 at Lang & Schwarz on October 19, 2026 at 9:00 a.m. CEST, 1.56 percent below the Xetra close of October 16, 2026 at EUR 2.57. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.